Craft

Merus

Stock Price

$51.9

2024-10-29

Market Capitalization

$3.6 B

2024-10-29

Revenue

$36.1 M

FY, 2024

Merus Summary

Company Summary

Overview
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The Company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.
Type
Public
Status
Active
Founded
2003
HQ
Utrecht, NL | view all locations
Website
http://www.merus.nl/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • John de Kruif

    John de Kruif, SVP & Chief Technology Officer

    • Mark Iwicki

      Mark Iwicki, Non-Executive Director

      • Hui Liu

        Hui Liu, EVP, Chief Business Officer & Head of Merus U.S

        • Len Kanavy

          Len Kanavy, Non-Executive Director

          LocationsView all

          2 locations detected

          • Utrecht, Utrecht HQ

            Netherlands

            62 Yalelaan

          • Cambridge, MA

            United States

            139 Main St #302

          Merus Financials

          Summary Financials

          Revenue (Q1, 2025)
          $26.5M
          Gross profit (Q1, 2025)
          $26.5M
          Net income (Q1, 2025)
          ($96.5M)
          Cash (Q1, 2025)
          $197.2M
          EBIT (Q1, 2025)
          ($75.7M)

          Footer menu